Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Abstract Text:

Fred Saad,Yin-Miao Chen,Donald M Gleason,Joseph Chin,Fred Saad,Yin-Miao Chen,Donald M Gleason,Joseph Chin,

PURPOSE: We previously reported the efficacy of zoledronic acid 4 mg versus placebo (every 3 weeks for 24 months) for the prevention of skeletal-related events (SREs) in men with advanced prostate cancer and bone metastases. We conducted several retrospective exploratory analyses to determine whether zoledronic acid has continuing efficacy during long-term treatment. PATIENTS AND METHODS: This report included analysis of the occurrence of SREs during the extension phase only (months 16-24), analysis of skeletal complications excluding the first SRE at 15 months (core phase), and stratified analysis of patients by history of SREs before study entry. RESULTS: Patients (N=422) were randomized to receive zoledronic acid 4 mg or placebo. For the 132 patients who entered the extension phase, zoledronic acid significantly delayed the onset of first SRE (P=.009) and decreased the risk of developing an SRE by 53% compared with placebo (P=.022). Among all 422 patients, zoledronic acid significantly reduced the incidence of a second on-study SRE (P=.017) and significantly delayed the median time to second SRE compared with placebo (P=.006) at 15 months. Among 144 patients (34%) with a history of SREs before study entry, zoledronic acid significantly reduced the skeletal morbidity rate by 65% (P=.036) and reduced the overall risk of developing an SRE by 40% (P=.028) compared with placebo at 24 months. CONCLUSION: This analysis confirms our previously reported results and suggests that long-term treatment with zoledronic acid provides continuing clinical benefit in patients with advanced prostate cancer, even after the occurrence of SREs.

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Publishing Authors By Initials

F Saad,YM Chen,DM Gleason,J Chin,F Saad,YM Chen,DM Gleason,J Chin,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical genitourinary cancer

VOLUME: 5

Page Numbers: 390-6

Journal Abbreviation:

ISSN: 1558-7673

DAY: 24

MONTH: Sep

YEAR: 2007

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101260955

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.

AFFILIATION: Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada. fred.saad@umontreal.ca

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Genitourin Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases Related Publications

• A comparison of DNA copy number profiling platforms.
• Acetylation-dependent signal transduction for type I interferon receptor.
• Altered partition of serum cholesterol and cholesteryl ester in a petroleum ether-ethanol-water system after incubation.
• CHF1/Hey2 plays a pivotal role in left ventricular maturation through suppression of ectopic atrial gene expression.
• Cell therapy in murine atherosclerosis: in vivo imaging with high-resolution helical SPECT.
• Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
• Do religious physicians disproportionately care for the underserved?
• Evaluation of lipid oxidation and oxidative products as affected by pork meat cut, packaging method, and storage time during frozen storage (-10 degrees C).
• Evolution and termination of a femtosecond laser filament in air.
• Following the call: how providers make sense of their decisions to work in faith-based and secular urban community health centers.
• Genome-wide mapping of RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by NF-kappaB upon TLR4 activation.
• Laryngeal nerve monitoring and minimally invasive thyroid surgery: complementary technologies.
• Logistic regression for disease classification using microarray data: model selection in a large p and small n case.
• Obstetric cholestasis in Hong Kong--local experience with eight consecutive cases.
• Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6.
• Performance and characteristics of an IR localizing system for radiation therapy.
• Phage immobilized magnetoelastic sensor for the detection of Salmonella typhimurium.
• Predictors of patient selection in bariatric surgery.
• Preparation and properties of electrophoretic microcapsules for electronic paper.
• Provider perceptions of limited health literacy in community health centers.
• Realization of complex onsets by pediatric users of cochlear implants.
• Reprogramming the amino-acid substrate specificity of orthogonal aminoacyl-tRNA synthetases to expand the genetic code of eukaryotic cells.
• Robotics and its applications in stereotactic radiosurgery.
• Scenario of a dirty bomb in an urban environment and acute management of radiation poisoning and injuries.
• Selective enrichment of DJ-1 protein in primate striatal neuronal processes: implications for Parkinson's disease.
• The cost-effectiveness of improving diabetes care in u.s. Federally qualified community health centers.
• Transcription factor CHF1/Hey2 regulates the global transcriptional response to platelet-derived growth factor in vascular smooth muscle cells.
• Trust and reciprocity: foundational principles for human subjects imaging research.
• Two cases of postmaturity-related perinatal mortality in non-local expectant mothers.
• Variation in consonant cluster production by pediatric cochlear implant users.